Skip to main content

Table 6 Distribution of risk classification for 3-month combined model and baseline model for refractory hyperthyroidism

From: Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study

 

Model A

Total

Class I

(< 52%)a

Class II

(52–71%)a

Class III

(≥ 71%)a

Model B (MMI ≥ 20 mg/day)

 Class I + (< 36%)a

15

8

0

23

20% (3/15)b

38% (3/8)b

(–)

 

 Class II + (36–63%)a

14

11

10

35

43% (6/14)b

55% (6/11)b

70% (7/10)b

 

 Class III + (63–83%)a

10

13

15

38

80% (8/10)b

62% (8/13)b

67% (10/15)b

 

 Class IV + (≥ 83%)a

0

6

12

18

(–)

100% (6/6)b

100% (12/12)b

 

 Total

39

38

37

114

Model C (MMI < 20 mg/day)

 Class I + (< 21%)a

61

0

0

51

13% (8/61)b

(–)

(–)

 

 Class II + (21–44%)a

45

13

0

58

29% (13/45)b

38% (5/13)b

(–)

 

 Class III + (44–63%)a

30

21

4

55

60% (18/30)b

52% (11/21)b

50% (2/4)b

 

 Class IV + (≥ 63%)a

8

24

26

58

50% (4/8)b

83% (20/24)b

85% (22/26)b

 

 Total

144

58

30

232

  1. aPredicted risk based on Models A, B and C
  2. bNumbers represent the actual number of refractory GD and the proportion in this group